MetrioPharm AG Investor Relations News
-
Investor Relations News Update
MetrioPharm announced that it is preparing a Phase II clinical trial for its lead compound MP1032 in the fight against COVID-19.
-
Investor Relations News Update
A Current Publication by Dr. Wolfgang Brysch on the Prevention and Treatment of Covid-19
-
Investor Relations News Update:
MetrioPharm Announces Publication of Successful MP1032 Preclinical Data in Covid-19
-
Investor Relations News QIII 2020:
A letter from Dr. Wolfgang Brysch, CEO of MetrioPharm AG
-
Investor Relations News QII 2020
Topics: 14th Annual General Meeting of MetrioPharm AG, Company Calendar
-
Investor Relations News QI 2020
Topics: Edison Report, Company Calendar
-
Investor Relations News
MetrioPharm’s work in times of Covid-19
-
Investor Relations News QIV 2019
Topics: Retrospect 2019, BIO-Europe, Jefferies London Healthcare Conference, Warburg Bank “Meet the future” Conference, Essay by CEO Dr. Wolfgang Brysch: "Who wants to live forever?" (Blog)
-
Investor Relations News QIII 2019
Topics: Greeting from CFO Sven Zimmermann, Investor Talks, Biotech Forum Basel, Company calendar, Interview with CFO Sven Zimmermann
-
Investor Relations News QII 2019
Topics: 13th Annual General Meeting of MetrioPharm AG, Events, Corporate Calendar of MetrioPharm AG, Employees, blog